Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Abstract
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.